FDA Releases New Safety Guidance for Compounded Semaglutide

The Food and Drug Administration has issued updated safety guidelines for compounded semaglutide preparations. This regulatory action addresses concerns about quality control, dosing accuracy, and contamination that arose during a shortage of the FDA-approved versions of the drug. The new guidance aims to mitigate risks associated with compounded products, which do not undergo the same pre-market review as their approved counterparts.